Increased Tissue Arachidonic Acid and Reduced Linoleic Acid in a Mouse Model of Cystic Fibrosis Are Reversed by Supplemental Glycerophospholipids Enriched in Docosahexaenoic Acid1–3
| Autor: | Patrick Lebecque, Pierre Wallemacq, Teresinha Leal, Myriam Mimoun, Jean Lebacq, Martine Armand, T. Coste |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
genetic structures Linoleic acid Medicine (miscellaneous) 030204 cardiovascular system & hematology Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Unsaturated fatty acid 030304 developmental biology chemistry.chemical_classification 0303 health sciences Nutrition and Dietetics Fatty acid metabolism food and beverages Fatty acid Metabolism 3. Good health Endocrinology chemistry Docosahexaenoic acid lipids (amino acids peptides and proteins) Arachidonic acid Polyunsaturated fatty acid |
| Zdroj: | The Journal of Nutrition. 139:2358-2364 |
| ISSN: | 0022-3166 |
| DOI: | 10.3945/jn.109.110999 |
| Popis: | An imbalance in (n-6)/(n-3) PUFA has been reported in cystic fibrosis (CF) patients. Glycerophospholipids enriched in docosahexaenoic acid (GPL-DHA) have been shown to regulate the (n-6)/(n-3) fatty acid ratio in the elderly. Here, we tested the effect of GPL-DHA supplementation on PUFA status in F508del homozygous CF mice. GPL-DHA liposomes were administrated by gavage (60 mg DHA/kg daily, i.e. at maximum 1.4 mg DHA/d) to 1.5-mo-old CF mice (CF+DHA) and their corresponding wild-type (WT) homozygous littermates (WT+DHA) for 6 wk. The PUFA status of different tissues was determined by GC and compared with control groups (CF and WT). There was an alteration in the (n-6) PUFA pathway in several CF-target organs in CF compared with WT mice, as evidenced by a higher level of arachidonic acid (AA) in membrane phospholipids or whole tissue (21 and 39% in duodenum-jejunum, 32 and 38% in ileum, and 19 and 43% in pancreas). Elevated AA levels were associated with lower linoleic acid (LA) and higher dihomo-gamma-linolenic acid levels. No DHA deficiency was observed. GPL-DHA treatment resulted in different PUFA composition changes depending on the tissue (increase in LA, decrease in elevated AA, DHA increase, increase in (n-6)/(n-3) fatty acid ratio). However, the DHA/AA ratio consistently increased in all tissues in CF+DHA and WT+DHA mice. Our study demonstrates the effectiveness of an original oral DHA formulation in counter-balancing the abnormal (n-6) fatty acid metabolism in organs of CF mice when administrated at a low dose and highlights the potential of the use of GPL-DHA as nutritherapy for CF patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|